Afficher la notice abrégée

Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine

dc.contributor.authorReischl, Gerald*
dc.date.accessioned2021-02-12T05:15:14Z
dc.date.available2021-02-12T05:15:14Z
dc.date.issued2019*
dc.date.submitted2019-12-09 11:49:15*
dc.identifier42527*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/60492
dc.description.abstractThis is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences.*
dc.languageEnglish*
dc.subjectR5-920*
dc.subjectRM1-950*
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.othern/a*
dc.subject.otherpretargeting*
dc.subject.otherradioiodination*
dc.subject.otherneurodegeneration*
dc.subject.otherphosphoramidon*
dc.subject.otherGRPR*
dc.subject.othermolecular imaging*
dc.subject.otherallosteric modulator*
dc.subject.otherradiosynthesis*
dc.subject.otherseparation*
dc.subject.other?-CIT.*
dc.subject.otherPET/CT imaging*
dc.subject.othertechnetium-99m*
dc.subject.othergastrin-releasing peptide receptor*
dc.subject.othermetabotropic glutamate receptor subtype 5*
dc.subject.otherglutamate*
dc.subject.otheroncogenic fusions*
dc.subject.otherFusarinine C*
dc.subject.otherhypoxia*
dc.subject.othertirapazamine (TPZ)*
dc.subject.other68Ga*
dc.subject.othersentinel lymph node*
dc.subject.other99mTc-radioligand*
dc.subject.otheriodine-131*
dc.subject.otherelectrophilic radioiodination*
dc.subject.other4-dioxide (BTDO)*
dc.subject.otherminigastrin*
dc.subject.otherceftriaxone*
dc.subject.othertropomyosin receptor kinase*
dc.subject.othercarbonic anhydrase IX*
dc.subject.otherABP688*
dc.subject.otherNPY(Y1)R*
dc.subject.otherMMPEP*
dc.subject.otherradiosensitizer*
dc.subject.otherneprilysin-inhibition*
dc.subject.otherradiochemistry*
dc.subject.othergirentuximab*
dc.subject.otherbenzotriazine-1*
dc.subject.othergallium-68*
dc.subject.othercholecystokinin-2 receptor*
dc.subject.othertumor targeting*
dc.subject.otherradioimmunotherapy*
dc.subject.othersalivary gland uptake*
dc.subject.othermetabolic stability*
dc.subject.othertumor hypoxia*
dc.subject.othermultimerization*
dc.subject.otheroxidizing agent*
dc.subject.otherneuroinflammation*
dc.subject.othergastrin-releasing peptide*
dc.subject.otherdextran*
dc.subject.othercarbon-11*
dc.subject.otherpeptide heterodimers*
dc.subject.otherapparent molar activity*
dc.subject.otherradiometals*
dc.subject.othermicroglia*
dc.subject.otherrituximab*
dc.subject.other[18F]FMISO*
dc.subject.other[11C]meta-hydroxyephedrine*
dc.subject.otherIodo-Gen®*
dc.subject.othermannose*
dc.subject.other177Lu-radiopharmaceuticals*
dc.subject.otherazomycin nucleosides*
dc.subject.otherbreast cancer*
dc.subject.otherclick chemistry*
dc.subject.othersmall animal imaging*
dc.subject.otherSR 4317*
dc.subject.otherbenzotriazine-1-monoxide (BTMO)*
dc.subject.otherbombesin*
dc.subject.otherprostate cancer*
dc.subject.otherChloramine T*
dc.subject.other99mTc-radiopharmaceuticals*
dc.subject.otherketamine*
dc.subject.otherPSMA-617*
dc.subject.otherpositron emission tomography*
dc.subject.otherhydrazinonicotinic acid (HYNIC)*
dc.subject.otherrenal cell carcinomas*
dc.subject.other[18F]PSS232*
dc.subject.otherPET*
dc.subject.otherendoradiotherapy*
dc.titleTargets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine*
dc.typebook
oapen.identifier.doi10.3390/books978-3-03921-314-6*
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0*
oapen.relation.isbn9783039213139*
oapen.relation.isbn9783039213146*
oapen.pages214*
oapen.edition1st*


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by-nc-nd/4.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/